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Smnumn Previous reports have shown the production of parathyroid hormone-related protein (PTHrP) by
breast cancer cells in vivo and in vitro. We have investigated the expression of the PTH'lTHrP receptor by the
human breast cancer cell lines MCF-7. ZR-75-1, T-47-D. SK-BR-3, Hs578T and MDA-MB231. Using reverse
transcription-polymerase chain reaction (RT-PCR) and Southern blot analysis, we detected transcripts for
the receptor in MCF-7, SK-BR-3 and MDA-MB231 cells. There was no evidence of receptor mRNA in
ZR-75-1 and Hs578T cells. Furthermore, Northern blot analysis of mRNA from MCF-7 cells showed two
transcripts of 1.5 and 2.4 kb which coded for the PTH TFHrP receptor. Expression of PTHTTHrP receptor
mRNA by the breast cancer cell lines was also correlated with the detection of PTHrP transcripts. RT-PCR
demonstrated PTHrP mRNA in MCF-7, ZR-75-1, T-47-D and Hs578T cells, but not in SK-BR-3 and
MDA-MB231 cells. The detection of receptor transcripts was complemented by [3Hlthymidine and
bromodeoxyuridine incorporation studies, in which mitogenic responses to PTH and PTHrP were observed in
MCF-7 cells but not in Hs578T cells. In response to both PTH(1-34) and PTHrP(1-34), quiescent MCF-7
cells proliferated in a similar dose-dependent manner (1.6- 100 ng ml-'). No mitogenic effects of these peptides
were observed with Hs578T cells. In addition, levels of intracellular cAMP were measured in MCF-7 and
Hs578T cells in response to PTHrP(1 -34). In MCF-7 cells there was a significant rise in cAMP with
100 ng mlP ' PTHrP(1 -34). The expression of PTH PTHrP receptor by breast cancer cells suggests that PTHrP
may be a paracrine autocrine regulator of breast carcinoma.
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Parathyroid hormone (PTH) is secreted by the parathyroid
glands and is a systemic hormone which regulates calcium
and phosphate homeostasis. PTH-related peptide (PTHrP)
has considerable N-terminus homology to PTH (Goltzman et
al., 1989; Martin and Suva, 1989), stimulates bone resorption
in vitro (Evely et al., 1990) and in vivo (Horiuchi et al., 1987)
and is known to mediate humoral hypercalcaemia of malig-
nancy (Broadus et al., 1988). Initially identified in tumour
cells (Burtis et al., 1987; Moseley et al., 1987; Stewart et al.,
1987; Strewler et al., 1987), PTHrP has now been localised in
several normal tissues and a range of fetal tissues (Moniz et
al., 1990) and, although the role of PTHrP has yet to be fully
elucidated, it probably acts as a paracrine/autocrine regulator
of cell function.
PTH and PTHrP exert their effects through cell-surface
receptors which were originally thought to be principally in
kidney and bone. Binding of the ligand to the receptor has
multiple effects, including elevation of intracellular cAMP
(Chase et al., 1969), [Ca2+] (Donahue et al., 1988; Schoefl et
al., 1991) and inositol phosphates (Cosman et al., 1989).
Expression cloning has identified a single PTH/PTHrP recep-
tor, which binds both PTH and PTHrP at high affinity
(Abou-Samra et al., 1992). In rat, transcripts for this receptor
have been identified in bone and kidney but also in many
other tissues, including breast (Urena et al., 1993). It has
therefore been proposed that this single receptor species
mediates many of the physiologically diverse actions of PTH
PTHrP throughout the body.
PTHrP can be identified in normal lactating mammary
tissue (Thiede and Rodan, 1988) and has been detected in
primary cultures of mammary epithelial cells (Ferrari et al.,
1992). In transgenic mice which overexpress human PTHrP
there is profound breast hypoplasia, suggesting an important
role for PTHrP in the regulation of mammogenesis
(Wysolmerski et al., 1993). The peptide has been isolated
from a mammary tumour (Burtis et al., 1987; Stewart et al.,
1987) and identified in cultures of breast cancer cells (Walsh
et al., 1992; Francini et al., 1993). In an immunocytochemical
Correspondence: MA Birch
Received 15 March 1994; revised 20 February 1995; accepted 23
February 1995
study, 60% of the human breast carcinomas investigated
expressed PTHrP (Southby et al., 1990). In addition,
immunocytochemistry (Bundred et al., 1991; Powell et al.,
1991) and in situ hybridisation (Vargas et al., 1992) have
revealed that a significant number of skeletal metastases aris-
ing from breast carcinoma express PTHrP. We have demon-
strated that the human breast cancer cell line Hs578T pro-
duces PTHrP, while MCF-7 cells do not (Walsh et al., 1992).
Furthermore, transcripts for PTHrP have been detected in a
primary human cell line, 8701 BC, which was isolated from a
primary ductal infiltrating carcinoma of the breast (Luparello
et al., 1993). These findings indicate that PTHrP expression
by breast cancer cells may play an important role in progres-
sion of the tumour. Expression of the PTH/MTHrP receptor
may confer autocrine/paracrine regulation of the breast
tumour cells by PTHrP. In this study we have investigated
the expression of the PTH/PTHrP receptor by human breast
cancer cell lines.
Materals and methods
Cell culture
ZR-75-1, T-47-D, SK-BR-3, MDA-MB231 (all gifts from
Professor P Rudland, Department of Biochemistry, Univer-
sity of Liverpool, UK), MCF-7 (a gift from Dr C Green,
Department of Biochemistry, University of Liverpool, UK)
and Hs578T (from ECACC, Porton Down, UK) and the
human osteosarcoma cell line, Saos-2 (a gift from Dr J
Beresford, Bath Institute of Rheumatic Diseases, UK) were
grown in minimum essential medium (DMEM) supplemented
with 10% fetal calf serum (FCS) (Sera Lab), 2 mM L-
glutamine (Gibco) and antibiotics (100 U ml-' penicillin,
100;Lg ml-' streptomycin) (Gibco).
Reverse transcription-linkedpolymerase chain reaction
(RT-PCR) analysis ofPTHIPTHrP receptor mRNA
expression
Total RNA was extracted from the cell monolayers in 9 cm
Petri dishes (Falcon) by the method of Chomczynski andSacchi (1987). RNA was used as a template for cDNA
synthesis in a 50yI1 volume containing the following reagents:
0.5 mM each of dATP, dCTP, dGTP, dTTP (Pharmacia),
2 jg of oligo-dT (Pharmacia), 20 U of RNAse inhibitor
(Boehringer), 10 mM dithiothreitol, 6 mM mag um
chlonde, 40 mM potasum chlonde, 50 mM Tris-CI (pH
8.3) and 200 U jg-I RNA of mouse Moloney leukaemia
virus (MMoLV) reverse transcriptase (Gibco). The reaction
was incubated at 3TC for 60min and stopped by freezing at
-20-C.
PCR analysis was performed using oligonucleotides which
were designed from the published sequence (Abou-Samra et
al., 1992) for the PTH/PTHrP receptor. The primers which
amplified a fragment of 571 bp were:
Sense: 5'-AGGAACAGATC-TCCTGCTGCA-3'
Antisense: 5'-TGCATGTGGATGTAGTTGCGCGT-3'
Primers for the detection of human PTHrP have previously
been described (Walsh et al., 1994).
The PCR reaction mixture (final volume 50 id) contained 1
unit of Tbermoprime (Advanced Biotechnologies), 0.5 jig of
each oligonucletide primer, 200#iM each of dATP, dCTP,
dGTP, dTTP, 1.5 m magnesium chloride, 10 mM
mercaptoethanol, 10mm Tris-HCI (pH 8.3) and 241 of the
cDNA template. The following thermal cycle was used: a
denaturation step of 94-C for 2 min followed by 30 cycles of
94 C for 30 s, 55C for 30 s, 72C for 30 s. The thermal cycle
for amplification of PTHrP products was identical except for
the annealing step, which was performed at 62C. PCR prod-
ucts were analysed by agarose gel eectrophoresis and
vilised by ethidium bromide staining under UV light.
PTH/PTHrP receptor amplification products were
identified by Southern blot analysis. Products were separated
by agarose gel eletrophoresis and blotted onto Hybond N
(Amersham). The PTH/PTHrP recptor probe was 571 bp
(corresponding to 131-702 bp of the human PTH receptor
mRNA, accession no. L04308) which had been cloned into
pBluescript (a gift from Dr D Evans, Ciba-Geigy, Basle,
Switzerland). The PTHrP probe was a 535 bp fragment of
PTHrP which had been cloned into pBluescript and
sequenced (Walsh et al., 1994). cDNA was labelled with[m-
12PJdCTP (specific activity 3000 Cimmol-') usng a random
pimed labeling kit (Boehringer). The blots were prehyb-
ridised for 2 h at 42-C in 40% formamide, 5 x SSC, 50 mM
phosphate buffer (pH 7), 1 x SDS, 10 xDenhardt's and
200 jigml-I denatured salmon sperm DNA (Sigma).
Denatured probe (5 x 107 c.p.m. per membrane) was added
diretly to the prehybridisation mix and incubated at 42-C
overnight. Membranes were washed three times in 0.2 x SSC/
1% SDS at 60 C for 20min and exposed to XO-mat film
(Kodak) with an intensifying screen at - 70'C.
Northern blot analysis
A 5 jg aliquot of poly(A) + RNA from MCF-7 cls was
fractionated on a formaldehyde agarose gel and transferred
to Hybond N (Amersham). The membrane was then prehyb-
ridised, hybridised and washed as described previously. The
membrane was then exposed to XO-mat film (Kodak) with
an intensifying screen at -70-C for 5 days.
Measurement ofthymidne incorporation
Cells were detached from the culture dish with 0.25% tryp-
sin, resuspended in DMEM/10% FCS and seeded into a
96-well plate at 5 x 104 cells per well. The plates were
incubated at 3TC for 72 h to ensure that all wells were
confluent, the medium removed and the wells washed once in
serum-free DMEM/0.1 % bovine serum albumin (BSA) and
100l I of fresh serum-free DMEM/0.1 % BSA was added to
each well. The wells were incubated for a further 4 days in
serum-free medium, after which the medium was again
replaced with 100 IlI of fresh medium/0.1% BSA containing
various concentrations of PTH(l-34) or PTHrP(l -34) (both
PmHvriwMp d c i
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Peninsula Labs). A 0.5 iCi aliquot of [3H]thymidine was then
added to each well and the plates were incubated for a
further 24 h. The plates were harvested with a cell harveser
and [H]thymidine incorporation measured by scntillation
counting.
Measurement ofbrmodeoxyrine uptake
Uptake of bromodeoxyuridine (BrdU) by MCF-7 cells was
assessed by immunocytochemical staining using an Amer-
sham cell proliferation kit (Amersham, UK). PTHrP
(100ngml-') was added to serum-free cukures of MCF-7
cells. After 20 h incubation at 37C bromodeoxyuridine label-
ling reagent was added. After a further 4 h incubation the
medium was removed from the dishes and the cell layers
were fixed in 90% ethanol/10% acetic acid. Immun-
ocytochemical detection of BrdU was then carried out using
mouse anti-BrdU followed by horseradish peroxidase-
coupled rat anti-mouse immunoglobulin and 2,3-diami-
nobenzidine as substrate. The dishes were examined micros-
copically and the percentage of dark-sning nuclei recorded
in each field. Three wells were used for each treatment and
ten fields examined in each well.
Measurement ofintracellular cyclic AMP levels
The cell line(s) to be investigated were seeded in DMEM/
10% FCS in six-well plates and grown to confluence. The
medium was then roved and replaced with serum-free
DMEM containing the phosphodiesterase inhibitor IILM 3-
isobutyl-l-methyl-xanthine (IBMX) (Sigma) and PTHrP as
appropriate. After 20 mm incubation with or without
PTHrP, the medium was removed and 0.5 ml of60% ethanol
added to each well. The cell layer was scraped into the
ethanol with a plastic transfer pipette and transferred to a
1.5 ml Eppendorf tube. The sample was then acetylated and
cAMP level measured by competitive radioimmunoassay as
previously described (O'Reilly et al., 1986).
Statistical aalysis
Statistical analysis was carried out by analysis of variance
(ANOVA), and significnce between groups determined by
Duncan's new multiple range test.
Res
Figure la shows RT-PCR analysis of PTH/PTHrP receptor
using cDNA from MCF-7, ZR-75-1, T-47-D, SK-BR-3,
Hs578T, MDA-MB231 and Saos-2 cells as template. The
quality of the cDNA had previously been veified by detec-
tion of several transcripts, incuding P-actin and
glycraldehyde-3-phosphate dehydrogenase (data not shown).
Bands of the predicted 571 bp were vible in the PCR
products from Saos-2, MCF-7 and SK-BR-3 clls. There
were no products visble in the reactions using ZR-75-1,
T-47-D, Hs578T and MDA-MB231 cDNA as template or in
negative controls. The products from Figure la were blotted
onto a nylon membrane and probed with a 32P-labelled TH/
PTHrP receptor cDNA (Figure lb). Specific hybridisation
was observed with the 571 bp products from Saos-2, MCF-7
and SK-BR-3, confirming the presece ofPTH/PITHrP recep-
tor transcripts. Additionally, weak Southem blot signals were
observed with MDA-MB231 and possibly T47D cDNA. The
expression of the PTH/PTHrP receptor by MCF-7 cells was
also demonstrated by Norther blot analysis (Figure 2).
The breast cancer cell lines were also investigated for the
expression of PTHrP mRNA. RT-PCR identified specific
535 bp products in Saos-2, MCF-7, ZR-75-1, T47-D and
Hs578T cells (Figure 3a), which was confirmed by Southern
blot analysis (Figure 3b).
Further studies of MCF-7 and Hs578T were performed in
order to determine whether the presence of PFH/PTHrPPTH/PTHrP - and ho cir
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Fuge I (a)Total RNA was isolated from confluent cultures of
Saos-2, MCF-7, ZR-75-1, T-47-D, SK-BR-3, Hs578T and MDA-
MB231 cells, and used in RT-PCR with primers specific for the
PTH/THrP receptor (see Materials and methods). Lane 1, 1 kb
marker (Gibco-BRL); lane 2, RT-PCR of Saos-2 cDNA showing
specific amplification of a 571 bp product; lane 3, MCF-7 PCR
products; lane 4, ZR-75-1 PCR products; lane 5, T-47-D PCR
products; lane 6, SK-BR-3 PCR products; lane 7, Hs578T PCR
products; lane 8, MDA-MB231 PCR products; lane 9, PCR of no
DNA negative control. (b) Southern blot of a probed with a
PP-labelled PTHfPTHrP receptor cDNA. Lane 1, 1 kb markeer
(Gibco-BRL); lane 2, RT-PCR of Saos-2 cDNA showing specific
amplification of a 571 bp product; lane 3, MCF-7 PCR products;
lane 4, ZR-75-1 PCR products; lane 5, T-47-D PCR products;
lane 6, SK-BR-3 PCR products; lane 7, Hs578T PCR products;
lane 8, MDA-MB231 PCR products; lane 9, PCR of no DNA
negative control.
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receptor mRNA was accompanied by the expression of a
functional receptor. Proliferation studies in response to
PTH(l-34) and PTHrP(I-34) were performed on MCF-7
and Hs578T cells by [3H]thymidine incorporation. Neither
peptide had any effect when added to rapidly proliferating
cells (data not shown). However, when the cells were made
quiescent by incubation in serum-free medium at confluence,
MCF-7 cells (Figure 4) proliferated in a dose-dependent
manner in response to PTHrP(I-34). All doses of PTHrP
between 1.6 and 100 ng ml-' significantly stimulated
[3HJthymidine uptake. In other experiments where PTH and
PTHrP were directly compared, the two molecules were app-
roximately equipotent in the stimulation of proliferation of
MCF-7 cells (Figure 5), but neither peptide increased the
uptake of [3Hjthymidine by Hs578T cells (Figure 6). Addi-
tionally, to confirm the [3H]thymidine data, studies were
performed on the uptake of BrdU by MCF-7 cells. Treat-
ment of cultures for 20 h with PTHrP (100 ng mlV') resulted
in 12.2 ± 3% (mean ± s.e.m.) of nuclei stained compared
with 2.6 ± 1% for control cultures.
Changes in intracellular cAMP levels were measured in
MCF-7 and Hs578T ceUs in response to PTHrP(I-34). In
MCF-7 ceUs there was a significant increase in the level of
intracellular cAMP when cultures were treated with
lOOngm[J' PTHrP(1-34) but no elevation at lOngm[-'
(Figure 7). In experiments with Hs578T cells (data not
shown) there was no significant change in the concentrations
of intracellular cAMP.
Fugwe 3 (a)Total RNA was isolated from confluent cultures of
Saos-2, MCF-7, ZR-75-1, T-47-D, SK-BR-3, Hs578T and MDA-
MB231 cells, and used in RT-PCR with primers specific for
PTHrP (see Materials and methods). Lane 1, 1 kb marker
(Gibco-BRL); lane 2, RT-PCR of Saos-2 cDNA showing specific
amplification of a 571 bp product; lane 3, MCF-7 PCR products;
lane 4, ZR-75-1 PCR products; lane 5, T-47-D PCR products;
lane 6, SK-BR-3 PCR products; lane 7, Hs578T PCR products;
lane 8, MDA-MB231 PCR products; lane 9, PCR of no DNA
negative control. (b) Southern blot of a probed with a 32P-labelled
PTHrP cDNA. Lane 1, 1 kb marker (Gibco-BRL); lane 2,
RT-PCR of Saos-2 cDNA showing specific amplification of a
57 bp product; lane 3, MCF-7 PCR products; lane 4, ZR-75-1
PCR products; lane 5, T-47-D PCR products; lane 6, SK-BR-3
PCR products; lane 7, Hs578T PCR products; lane 8. MDA-
MB231 PCR products; lane 9, PCR of no DNA negative control.
Discusso
This study has demonstrated that transcripts for the PTH/
PTHrP receptor can be detected by RT-PCR in the human
breast cancer cell lines, MCF-7 and SK-BR-3 and the
osteosarcoma cell line, Saos-2. In addition, Southern blot
analysis detected receptor expression in MDA-MB231 and
possibly in T-47-D cells. The receptor was not identified in
ZR-75-1 or Hs578T cells. PTH and PTHrP were reportedly
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Fugwe 4 Effect of PTHrP on [3H]thymidine incorporation by
MCR-7 cells. MCF-7 cells were seeded into a 96-well plate at
5 x 104 cells per well and grown to confluence. The cells were
then incubated in serum-free medium for 4 days. The medium
was then replaced with fresh medium containing 0.4- 100 ngmlrl'
PTHrP( -34) and 0.5pCi of [3H]thymidine. The plates were
incubated for a further 24h, cells harvested and [3Hlthymidine
incorporation measured by scintillation counting. All data
represented as means + s.e.m. (n = 6). Asterisk denotes
significance (P<0.05).
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Fugwe 6 Effect of PTH (U) and PTHrP (0) on [3H]thymidine
incorporation by Hs578T cells. Hs578T cells were seeded into a
96-well plate at 5 x IOW cells per well and grown to confluence.
The cells were then incubated in serum-free medium for 4 days.
The medium was then replaced with fresh medium containing
0.4-100 ngml-' PTH(1-34) or PTHrP(l-34) and 0.5pCi of
[3HJthymidine. The plates were incubated for a fiurther 24 h, cells
harvested and [3HJthymidine incorporation measured by scintilla-
tion counting. All data represented as means + s.e.m. (n = 3).
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Fugwe 5 Effect of PTH (U) and PTHrP (0) on [3H]thymidine
incorporation by MCF-7 cells. MCF-7 cells were seeded into a
96-well plate at 5 x 10' cells per well and grown to confluence.
The cells were the incubated in serum-free medium for 4 days.
The medium was then replaced with fresh medium containing
0.4-100 ngml.1' PTH(I-34) or PTHrP(I-34) and 0.5MCi of
[3H]thymidine. The plates were incubated for a further 24 h, cells
harvested and [3H]thymidine incorporation measured by scintilla-
tion counting. All data represented as means + s.e.m. (n = 3).
detected in cultures of breast cancer cells isolated from a
patient with humoral hypercalcaemia of malignancy (Fran-
cini et al., 1993), and we have previously detected PTHrP
transcripts in MCF-7 and Hs578T cells and immunoreactive
peptide in Hs578T cells but not in MCF-7 cells (Walsh et al.,
1992). In the data presented here transcripts for PTHrP were
detected in MCF-7, ZR-75-1, T-47-D and Hs578T cells. The
failure to detect PTH/PTHrP receptor mRNA in ZR-75-1
and Hs578T cells may be due to constitutive lack of expres-
sion or, alternatively, down-regulation as a result of PTHrP
production, as has been suggested from studies of rat vas-
cular tissue in which high PTHrP mRNA levels are
associated with low PTH/PTHrP transcripts and vice versa
FuWe 7 Effect of PTHrP(I-34) on intracellular cAMP in
MCF-7 cells. Cells were grown to confluence in six-well plates
and incubated with IBMX/PTHrP for 20 min. Cell layers were
harvested as described in Materials and methods and cAMP
determined by RIA. All data represented as mean + standard
deviation (n=6). Asterisk denotes significance (P<0.05).
(Okano et al., 1994). Further study is required to determine if
endogenous production of PTHrP can modulate the expres-
sion of PTH/PTHrP receptor in breast cancer cells.
PTH(I-34) and PTHrP(I-34) modulated the proliferation
of MCF-7 cells but had no effect on Hs578T cells. Further-
more, in response to PTHrP(1-34) (l00ngml-'), intracel-
lular levels of cAMP were elevated in MCF-7 cells but not
Hs578T cells. PTH(I-34) and PTHrP(I-34) stimulated
[3Hlthymidine incorporation by MCF-7 cells equipotently,
suggesting that both hormones mediate their effects through
the same receptor. PTH and/or PTHrP has previously been
reported to stimulate the proliferation of other cell types,
including osteoblasts (MacDonald et al., 1986), human renal
carcinoma cells (Burton et al., 1990) and Walker 256 car-
cinoma cells (Benitez-Verguizas and Esbrit, 1994).
These results indicate that PTH and PTHrP may be
growth factors for breast cancer cells and may play a
significant role in the progression of malignancy. PTH and
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PTHrP have been shown to stimulate the production of
matrix-degrading enzymes, including plasminogen activator
(PA), in other cell types (Hamilton et al., 1984). If PA
production was linked to PTH/PTHrP receptor activation in
breast cancer cells this would have major implications for
metastasis. In addition, other work has shown that PTHrP
expression by MDA-231 cells is stimulated by an extracel-
lular matrix produced by bone cells (Guise et al., 1994.
PTHfPTHrP receptor transcripts have an apparent widesp-
read tissue distribution (Urena et al., 1993), and we have
shown that breast cancer cells express the receptor and res-
pond to PTH/PTHrP. There is some evidence that primary
hyperparathyroidism can be associated with increased
incidence of malignancies (Farr et al., 1973). A mitogenic
effect of PTH on cancer cells could be one mechanism to
explain this observation, but further work is required to
confirm this.
Subclones of the 8701 BC primary breast cancer cell line
can be subdivided according to their ability to express
PTHrP mRNA, with PTHrP-positive clones displaying a
more aggressive growth behaviour than PTHrP-negative
clones in vitro (Luparello et al., 1993). In addition, an
RT-PCR study of 38 normocalcaemic breast cancer patients
with long-term follow-up demonstrated higher levels of
PTHrP expression in patients who subsequently developed
bone metastases (Bouizar et al., 1993). In the data presented
here we have shown the presence of PTHI-/PTHrP receptor
mRNA in four out of six breast cancer cell lines, and one of
these, MCF-7, was shown to proliferate in response to
PTH(l-34) and PTHrP(1-34). We conclude that PTHrP
may be an important autocrine/paracrine factor in the pro-
gression of breast cancer.
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